The role of genius is not to complicate the simple, but to simplify the complicated.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
imagine a savings account with a stated interest rate of 5%. If $100 were deposited, the income generated by the account would equal $5. This relationship can also be expressed as a multiple: $100 = 20 x $5. The 5% interest rate on the account equates to a 20x multiple investment. Values, rates of return and multiples are all part of the same equation.
The discounted free cash flow method is based on the same concepts except it also allows for a more customized income stream. In the DCF, the valuator uses a financial model to forecast the timing and magnitude of each cash flow over a number of years. Each of those is then individually discounted to the present value based on the required rate of return. The method is particularly helpful for valuing companies that expect uneven growth going forward or for modeling transactions with synergistic benefits. The DCF has come to be one of the most widely used methods because of its sound foundation in valuation theory and its flexibility.
Current share price is not a factor. Current share price only serves to reveal how much (or little) the market has mispriced the a share.
Good point!
A follow up question, in a hospital/covid treatment setting, would icosapent ethyl be more easily applied via IV if it weren't encapsulated to begin with?
I'm saying, if there is too little API, maybe, the country of origin, might not allow export of the API.
I would be hesitant to seek too much prepare-it success. Why? Because all the API manufacturing facilities are in foreign countries, are they not?
Anyone have any insight about ACST? Why? So much trade volume day after day? There is no pipeline, right?
Pilot Study Finds the Triglyceride Lowering Drug Vascepa May Improve COVID-19 Symptoms
https://www.everydayhealth.com/coronavirus/pilot-study-finds-triglyceride-lowering-drug-vascepa-may-improve-covid-19-symptoms/
order flow velocity is ridiculous
Anyone else have ihub level2 service?
It's an anomaly, and not during active trading,
Yet still delightful to dream. The ask is $150.
Is 45 minutes typical, or longer than usual and perhaps in line with having much to reveal?
in a single sentence:
Hikma’s removal of the CV Limitation of Use from the Hikma Label demonstrates Hikma’s specific intent to induce infringement of the Asserted Patents.
the introduction of mochida patent, licensed exclusively by amarin, changes the parameters, does it not, HDGabor?
Will Vascepa Train Roll Past Negative Omega-3 Results?
— STRENGTH, OMEMI temper enthusiasm but may not change much
https://www.medpagetoday.com/cardiology/prevention/89875?xid=nl_mpt_DHE_2020-11-25&eun=g207787d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=Daily%20Headlines%20Top%20Cat%20HeC%20%202020-11-25&utm_term=NL_Daily_DHE_dual-gmail-definition
'Where am I wrong? Are we to believe that insurance will not cover at least 55% for the drug that reduces CVD by 25+% and does not have a competitor label? "
"Can a system work where Amarin uses a central national dispensary like an Amazon pill pack to dispense $9/month (perhaps even more deeply discounted terms for those committing to a year's supply upfront) to dispense (with a valid prescription) Vascepa directly to the pts home? Since the copay and generic price will be similar -let the patient get it directly from this intermediary. I firmly think Amarin should have an "indigent" program for those customers who cannot afford the $9/month out of pocket and are on state Medicaid to directly capture this very substantial market. It would hugely build the market overnight.
HK"
This is indeed visionary but expect the vested interests in the current system to fight against it tooth and nail. Because you would be pushing money away from profit-motivated intermediaries toward either endpoint, I.e., amarin and the consumer.
"Who is making this presumption?"
That would be the FDA then everyone falls in line because of their presumption.
"I swear if a man's whisky or beer was even 10% diluted for a lesser price even, or reduced in volume, there would be rioting outside every bar and capital building across the nation, but dilute and substitute a man's Vascepa and no one gives a damn.
HK"
No one asked me, but if we were to take the 3rd party payers out of the system, forcing the consumer to always foot the entire purchase cost, it would be the same as your "whisky or beer" analogy.
Which goes back to my earlier point, vascepa is only less expensive than icosapent ethyl when the consumer introduces the coupon into the purchase transaction. and it is up to the consumer to be aware of, and utilize the coupon.
OT: crazy volume on acasti ACST for some unknown reason
I think there are two presumptions (accurate or not operating here in the supply chain.
1. The generic and the branded are sufficiently equivalent.
2. Given #1, most consumers will desire the lesser cost option, which is most often the generic.
Consumer beware! if you dont want generic, state so it the pharmacist.
"Is the pharmacist required to notify the patient of the switch, especially if the out of pocket cost (after Amarin's coupon is applied) is the same or if V is cheaper? "
I understand that awareness of the coupon is the patient's responsibility, not the pharmacy's/pharmacist's.
IPE was found to be cost effective with an incremental cost of $16,660 or $21,890 per QALY gained, respectively, which are both well below the most stringent typical criteria for assessing cost-effectiveness of medical therapy.
And retail price is now < $4000/yr!?!?
European Heart Journal - Cardiovascular Pharmacotherapy, pvaa128,
https://doi.org/10.1093/ehjcvp/pvaa128
Published:
02 November 2020
Bold move
"But based upon our view of the market opportunity, which is substantial, and based upon our -- both our experience with supply and knowledge and public comments from some of the generic companies, we believe that we can grow the market in the United States faster than what they can do in terms of supply in the market, probably good for everybody. "
.5M traded premarket, because of scripts?
"Unnecessary. The existence of direct infringement is not a question. But it is not enough, specific action should be proved also. "
So manufacturing of generic icosapent ethyl is not "specific action" but encapsulation, packaging and importation then ultimately consumption by patients with the reduce-it indication, is? Or is not?
I keep going back to production limits. If jointly the generic icosapent ethyl manufacturers produce more generic icosapent ethyl than is required to treat patients with triglycerides >500, the excess production is intended for sale to patients with the reduce-it indication.
Thanks to terrapharma on Twitter
https://m.scirp.org/papers/103416
Under the topic, I did not know this:
The generics are widely available and low priced pharmaceutical products but the quality of the main component and the composition of the additives are not fully transparent. Comparisons of the biological equivalence and long-term storage of the branded and generic products are performed **using parameters such as the maximum drug concentration, area under the blood concentration time curve and maximum drug concentration time.**
"gV
Must have 1g of icosapent ethyl. May not need to be 96% pure (we dont know this yet).
Inactive ingredients may differ."
What I understand you saying is, the capsule will be even larger than it already is?
"a sign on the shelf said "Omega-3's may be useful for DES" - I was pretty damn surprised by that!"
I've used vascepa daily for 7 yrs for dry eyes. Works well enough I dont need any eye drops.
Is that long buying or short covering, in 10k chunks premarket? Either way, the market is aware of a different risk level.
"@ Dancing I guess they will add the side effects but they don't need to add the data."
But see, that's my point. It's nonsensical to state on fhe generic label that "side effect xyz occurs in n% of the population" without explaining the population and why they were treated.
The population and why the population were treated is clearly REDUCE-IT data.
"I don't think infringement applies to side effects. "
Why would they add the side effect info to the label without the trial data that detected said side effect(s)?
"FDA sent Teva a letter in response to the de-listing of certain GSK patents from the Orange Book ..."
Sure would like to read that letter, is it public information? Who requested the "de-listing" and under what circumstances did the de-listing occur?
super simplification ...
If this case law holds through appeal,
Doesnt matter what (or how) you say to who about generic icosapent ethyl. if you produce more than is necessary to treat the skinny label patient population, you can be found to be inducing infringment on the other indication(s).
Sounds like a legal case where the generic manufacturer sue the insurers to recover a part of the treble damages incurred by the generic manufacturer when the insurers substituted generic for brand when the skinny label didn't allow that substitution.
Meanwhile the branded marketer already has their treble damages while the generics go after the insurers.
Consider this, if generic manufacturers assist in increasing the total sales of icosapent ethyl/ vascepa at no additional cost to amarin then amarin successfully sues for treble damages, has amarin generated more revenues than they would have otherwise with their own DTC and sales team?
Ya don't say ...
Teva argued that it could not be liable for induced
infringement because it had deliberately omitted, or
“carved out” from its 2007 label, reference to congestive
heart failure. Teva’s Rule 30(b)(6) witness, Director of New
Products Jennifer King, explained:
Question: So is the expectation of Teva that when
you carve out a particular indication, that Teva will
still get sales of that drug for that indication once
it’s launched its product?
Answer: It’s a legal strategy, not a commercial
strategy.
***
Question: And so to make it specific to the issues
here, if Teva has carved out congestive heart
failure, but not hypertension and not post MILVD,
Teva still expects to get sales where the doctor
prescribed carvedilol for congestive heart failure,
correct?
Answer: Yes, unless the doctor feels strongly.
Question: Writes brand only?
Answer: Yes.
Trial Tr., June 13, 2017, at 488.